BACKGROUND Coronavirus disease 2019(COVID-19)pandemic is still evolving globally,and Brazil is currently one of the most affected countries.It is still debated whether patients with inflammatory bowel disease(IBD)are ...BACKGROUND Coronavirus disease 2019(COVID-19)pandemic is still evolving globally,and Brazil is currently one of the most affected countries.It is still debated whether patients with inflammatory bowel disease(IBD)are at a higher risk for developing COVID-19 or its complications.AIM To assess geographical distribution of IBD patients at the highest risk and correlate these data with COVID-19 mortality rates in Brazil.METHODS The Brazilian IBD Study Group(Grupo de Estudos da Doença Inflamatória Intestinal do Brasil)developed a web-based survey adapted from the British Society of Gastroenterology guidelines.The included categories were demographic data and inquiries related to risk factors for complications from COVID-19.Patients were categorized as highest,moderate or lowest individual risk.The Spearman correlation test was used to identify any association between highest risk and mortality rates for each state of the country.RESULTS A total of 3568 patients(65.3%females)were included.Most participants were from the southeastern and southern regions of Brazil,and 84.1%were using immunomodulators and/or biologics.Most patients(55.1%)were at moderate risk,23.4%were at highest risk and 21.5%were at lowest risk of COVID-19 complications.No association between the proportion of IBD patients at highest risk for COVID-19 complications and higher mortality rates was identified in different Brazilian states(r=0.146,P=0.467).CONCLUSION This study indicates a distinct geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of the country,which may reflect contrasting socioeconomic,educational and healthcare aspects.No association between high risk of IBD and COVID-related mortality rates was identified.展开更多
文摘BACKGROUND Coronavirus disease 2019(COVID-19)pandemic is still evolving globally,and Brazil is currently one of the most affected countries.It is still debated whether patients with inflammatory bowel disease(IBD)are at a higher risk for developing COVID-19 or its complications.AIM To assess geographical distribution of IBD patients at the highest risk and correlate these data with COVID-19 mortality rates in Brazil.METHODS The Brazilian IBD Study Group(Grupo de Estudos da Doença Inflamatória Intestinal do Brasil)developed a web-based survey adapted from the British Society of Gastroenterology guidelines.The included categories were demographic data and inquiries related to risk factors for complications from COVID-19.Patients were categorized as highest,moderate or lowest individual risk.The Spearman correlation test was used to identify any association between highest risk and mortality rates for each state of the country.RESULTS A total of 3568 patients(65.3%females)were included.Most participants were from the southeastern and southern regions of Brazil,and 84.1%were using immunomodulators and/or biologics.Most patients(55.1%)were at moderate risk,23.4%were at highest risk and 21.5%were at lowest risk of COVID-19 complications.No association between the proportion of IBD patients at highest risk for COVID-19 complications and higher mortality rates was identified in different Brazilian states(r=0.146,P=0.467).CONCLUSION This study indicates a distinct geographical distribution of IBD patients at highest risk for COVID-19 complications in different states of the country,which may reflect contrasting socioeconomic,educational and healthcare aspects.No association between high risk of IBD and COVID-related mortality rates was identified.
